Ultromics, a AI startup which seeks to leverage the technology to diagnose coronary heart disease, has closed a £10m Series A.
The round was led by Oxford Sciences Innovation (OSI), and drew support from Netpute, RT Ventures, GT Healthcare, Fushia and Tanarra.
Angel investors Andre Crawford-Brunt and Dieter Spälti also participated.
According Tech.eu, Ultromics has developed proprietary technology known as ‘Topological Analysis’, which allegedly helps to improve the accuracy of diagnosis.
The tech is being trialled at six NHS Hospitals and is expected to be extended into 20.
Ross Upton, the CEO and founder, said: “Our goal is to increase accuracy, consistency and efficiency in cardiology, providing patients with a reliable test and significant saving for healthcare systems worldwide,” said Upton. “We’re delighted that we’ve secured this funding so we can commercialize this exciting technology and bring its benefits to patients everywhere.”
The funding will used to continue R&D, launch the technology in the US and the UK.